-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61

Benzinga·07/22/2026 13:11:38
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $67 to $61.